Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.48 |
| ▸ | MAP3K8 | P41279 | 4/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534236 | 0.80 | MAP3K8 (0.59) | EGFRERBB2MAP3K8MAPK13SRC | |
| SCHEMBL4774110 | 0.76 | MAP3K8 (0.74) | EGFRERBB2MAP3K8MAPK13SRC | |
| SCHEMBL6644272 | 0.73 | EGFR (0.69) | EGFRERBB2GAK | |
| SCHEMBL7563757 | 0.72 | EGFR (0.71) | EGFRERBB2MAP3K8MAP2K1GAK | |
| SCHEMBL4770213 | 0.69 | MAP3K8 (0.80) | EGFRERBB2MAP3K8MAPK13SRC | |
| SCHEMBL4769843 | 0.69 | MAP3K8 (0.75) | EGFRERBB2MAP3K8MAPK13SRC | |
| SCHEMBL4769778 | 0.69 | EGFR (0.68) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL4774425 | 0.68 | MAP3K8 (0.76) | EGFRERBB2MAP3K8MAPK13SRC | |
| SCHEMBL6642786 | 0.68 | EGFR (0.70) | EGFRERBB2GAK | |
| SCHEMBL6643911 | 0.68 | EGFR (0.70) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | AMERICAN CYANAMID COMPANY | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | ABL1, ROS1, ALK | EGFR 14/4885ERBB2 4/4885MAP3K8 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.